{
  "symbol": "NUTX",
  "company_name": "Nutex Health Inc",
  "ir_website": "https://www.nutexhealth.com/investors/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "NUTEX HEALTH REPORTS SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2024 FINANCIAL RESULTS",
          "url": "https://www.nutexhealth.com/nutex-health-reports-second-quarter-and-six-months-ended-june-30-2024-financial-results/",
          "content": "[Skip to content](#fl-main-content)\n\n[![Nutex Health](https://www.nutexhealth.com/wp-content/uploads/2020/10/nutex-health-logo-color-blue-lined-circle-2.png)](https://www.nutexhealth.com/)\n\n☏ 713-660-0557 ✉ info@nutexhealth.com\n\n[Facebook](https://www.facebook.com/nutexhealth/)[Twitter](https://twitter.com/nutexhealth)[Linkedin](https://www.linkedin.com/company/nutex-health-inc)\n\n[![Nutex Health](https://www.nutexhealth.com/wp-content/uploads/2020/10/nutex-health-logo-color-blue-lined-circle-2.png)](https://www.nutexhealth.com/)\n\n#  NUTEX HEALTH REPORTS SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2024 FINANCIAL RESULTS \n\nBy [](https://www.nutexhealth.com/author/) | August 8, 2024\n\n  * **_TOTAL REVENUE OF $143.5 MILLION FOR THE FIRST HALF 2024 VS $115.3 MILLION FOR THE FIRST HALF 2023, AN INCREASE OF 25%_**\n  * **_HOSPITAL DIVISION VISITS OF 81,276 FOR THE FIRST HALF 2024 VS VISITS OF 65,244 FOR THE FIRST HALF 2023, AN INCREASE OF 25%_**\n  * **_HOSPITAL DIVISION OPERATING INCOME OF $33.3 MILLION FOR THE FIRST HALF 2024 VS $13.9 MILLION FOR THE FIRST HALF 2023, AN INCREASE OF 140%_**\n  * **_NET CASH FROM OPERATING ACTIVITIES OF $16.3 MILLION FOR THE FIRST HALF 2024_**\n  * **_COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW_**\n\n\n\nHOUSTON, Aug. 8, 2024 — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in nine states and primary care-centric, risk-bearing physician networks, today announced second quarter 2024 financial results for the three and six months ended June 30, 2024.\n\n**Financial Highlights for the Three Months Ended June 30, 2024:**\n\n  * Total revenue of $76.1 million as compared to total revenue of $58.9 million for the three months ended June 30, 2023, an increase of 29%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 13.2% in 2024 compared to the same period in 2023.\n  * Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $3.5 million for the three months ended June 30, 2023. This includes non-cash impairment of assets of $3.5 million, non-cash impairment of goodwill of $3.2 million and $3.1 million non-cash gain on warrant liability.\n  * EBITDA, attributable to Nutex Health Inc. of $8.5 million as compared to EBITDA, attributable to Nutex Health Inc. of $3.7 million for the three months ended June 30, 2023.\n  * Adjusted EBITDA, attributable to Nutex Health Inc. of $12.0 million as compared to Adjusted EBITDA, attributable to Nutex Health Inc. of $4.0 million for the three months ended June 30, 2023, an increase of 200%.\n  * Total visits from the Hospital Division were 41,208 for the second quarter 2024 as compared to 32,183 for the second quarter 2023, an increase of 9,025 or 28.0%. Of this visit growth, mature hospitals increased by 10.3% in 2024 compared to the same period in 2023.\n\n\n\n**Financial Highlights for the Six Months Ended June 30, 2024:**\n\n  * Total revenue of $143.5 million as compared to total revenue of $115.3 million for the six months ended June 30, 2023, an increase of approximately 25%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 10.0% in 2024 compared to 2023.\n  * Net loss attributable to Nutex Health Inc. of $0.7 million as compared to net loss attributable to Nutex Health Inc. of $8.6 million for the six months ended June 30, 2023. This includes non-cash impairment of assets of $3.5 million, non-cash impairment of goodwill of $3.2 million and $5.7 million non-cash gain on warrant liability in the first six months of 2024.\n  * EBITDA, attributable to Nutex Health Inc. of $15.6 million as compared to EBITDA, attributable to Nutex Health Inc. of $4.1 million for the six months ended June 30, 2023.\n  * Adjusted EBITDA, attributable to Nutex Health Inc. of $16.6 million as compared to Adjusted EBITDA, attributable to Nutex Health Inc. of $6.4 million for the six months ended June 30, 2023, an increase of 159%.\n  * Total visits from the Hospital Division were 81,276 for the six months ended June 30, 2024 as compared to 65,244 for the same period in 2023, an increase of 16,032 or 24.6%. Of this visit growth, mature hospitals increased by 9.7% in the six months ended June 30, 2024 compared to the same period in 2023.\n  * Net cash from operating activities of $16.3 million. As of June 30, 2024, the Company had total assets of $422.4 million, including cash and cash equivalents of $40.8 million and long-term debt of $22.4 million.\n\n\n\nNote: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.\n\n“We are pleased to report 29% revenue growth, Adjusted EBITDA, attributable to Nutex Health Inc. of $12.0 million and a 150% increase in hospital division operating income to $22.8 million in the second quarter ended June 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability,” stated Jon Bates, Chief Financial Officer of Nutex Health.\n\n“Nutex Health is executing extremely well, and we plan to continue to advance our strategic initiatives to drive sustainable growth. We delivered solid revenue growth while accelerating cash flow and strengthening our balance sheet in the first half of 2024. We are confident that we are taking the right steps to lay the foundation for long-term success and to increasing shareholder value,” stated Warren Hosseinion, M.D., President of Nutex Health.\n\n“We had a solid Second Quarter with strong year over year growth. Volume continues to increase overall among our hospitals. Our average payment by insurers of patient claims increased, a trend we are optimistic will persist as we continue to work the NSA claims through the Independent Dispute Resolution process,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.\n\nFor more details on the Company’s Second Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at _[www.sec.gov](https://c212.net/c/link/?t=0&l=en&o=4229686-1&h=224454716&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov)_.\n\n**NUTEX HEALTH INC.** **CONDENSED CONSOLIDATED BALANCE SHEETS** (Unaudited)  \n---  \n**June 30, 2024** |  **December 31, 2023**  \n**Assets**  \nCurrent assets:  \nCash and cash equivalents |  $ |  40,807,975 |  $ |  22,002,056  \nAccounts receivable |  60,658,832 |  58,624,301  \nAccounts receivable – related parties |  4,577,189 |  4,152,068  \nInventories |  2,759,448 |  3,390,584  \nPrepaid expenses and other current assets |  5,066,994 |  2,679,394  \nTotal current assets |  113,870,438 |  90,848,403  \nProperty and equipment, net |  78,881,900 |  81,387,649  \nOperating right-of-use assets |  11,690,957 |  11,853,082  \nFinance right-of-use assets |  187,096,271 |  176,146,329  \nIntangible assets, net |  16,180,504 |  20,512,636  \nGoodwill, net |  13,918,719 |  17,066,263  \nOther assets |  764,462 |  431,135  \nTotal assets |  $ |  422,403,251 |  $ |  398,245,497  \n**Liabilities and Equity**  \nCurrent liabilities:  \nAccounts payable |  $ |  16,742,370 |  $ |  18,899,196  \nAccounts payable – related parties |  6,796,475 |  6,382,197  \nLines of credit |  2,909,296 |  3,371,676  \nCurrent portion of long-term debt |  14,223,944 |  10,808,721  \nOperating lease liabilities, current portion |  1,998,512 |  1,579,987  \nFinance lease liabilities, current portion |  5,570,604 |  4,315,979  \nAccrued expenses and other current liabilities |  23,417,191 |  12,955,296  \nTotal current liabilities |  71,658,392 |  58,313,052  \nLong-term debt, net |  22,406,516 |  26,314,733  \nWarrant liability |  2,000,714 |  –  \nOperating lease liabilities, net |  14,690,566 |  15,479,639  \nFinance lease liabilities, net |  226,820,535 |  213,886,213  \nDeferred tax liabilities |  2,804,492 |  5,145,754  \nTotal liabilities |  340,381,215 |  319,139,391  \nCommitments and contingencies  \nEquity:  \nCommon stock, $0.001 par value; 950,000,000 shares authorized; 4,987,268 and 4,511,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively |  4,988 |  4,511  \nAdditional paid-in capital |  472,529,641 |  470,521,218  \nAccumulated deficit |  (409,800,662) |  (409,072,539)  \nNutex Health Inc. equity |  62,733,967 |  61,453,190  \nNoncontrolling interests |  19,288,069 |  17,652,916  \nTotal equity |  82,022,036 |  79,106,106  \nTotal liabilities and equity |  $ |  422,403,251 |  $ |  398,245,497  \n  \n**NUTEX HEALTH INC.** **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** (Unaudited)  \n---  \n**Three Months Ended June 30,** |  **Six Months Ended June 30,**  \n**2024** |  **2023** |  **2024** |  **2023**  \nRevenue:  \nHospital division |  $ |  67,604,878 |  $ |  51,611,803 |  $ |  127,634,247 |  $ |  100,899,967  \nPopulation health management division |  8,477,383 |  7,312,651 |  15,901,801 |  14,353,904  \nTotal revenue |  76,082,261 |  58,924,454 |  143,536,048 |  115,253,871  \nOperating costs and expenses:  \nPayroll and benefits |  28,398,075 |  24,860,702 |  55,401,219 |  50,697,375  \nContract services |  9,505,222 |  9,747,873 |  20,824,676 |  18,937,204  \nMedical supplies |  3,588,464 |  3,264,202 |  8,910,306 |  7,288,084  \nDepreciation and amortization |  4,532,804 |  4,169,160 |  8,719,006 |  8,162,907  \nOther |  7,496,465 |  7,235,594 |  16,962,432 |  15,673,655  \nTotal operating costs and expenses |  53,521,030 |  49,277,531 |  110,817,639 |  100,759,225  \nGross profit |  22,561,231 |  9,646,923 |  32,718,409 |  14,494,646  \nCorporate and other costs:  \nFacilities closing costs |  – |  – |  – |  217,266  \nStock-based compensation expense |  (61,241) |  249,645 |  (12,074) |  2,149,645  \nImpairment of assets |  3,473,635 |  – |  3,473,635 |  –  \nImpairment of goodwill |  3,197,391 |  – |  3,197,391 |  –  \nGeneral and administrative expenses |  10,652,390 |  9,759,816 |  19,310,800 |  16,935,360  \nTotal corporate and other costs |  17,262,175 |  10,009,461 |  25,969,752 |  19,302,271  \nOperating income (loss) |  5,299,056 |  (362,538) |  6,748,657 |  (4,807,625)  \nInterest expense, net |  5,054,532 |  4,843,048 |  9,498,894 |  7,983,137  \nGain on warrant liability |  (3,060,096) |  – |  (5,660,843) |  –  \nOther (income) expense |  (599,502) |  (123,528) |  (840,694) |  123,927  \nIncome (loss) before taxes |  3,904,122 |  (5,082,058) |  3,751,300 |  (12,914,689)  \nIncome tax expense (benefit) |  893,892 |  (815,612) |  1,283,557 |  (1,726,271)  \nNet income (loss) |  3,010,230 |  (4,266,446) |  2,467,743 |  (11,188,418)  \nLess: net income (loss) attributable to noncontrolling interests |  3,374,278 |  (787,399) |  3,195,866 |  (2,562,092)  \nNet loss attributable to Nutex Health Inc. |  $ |  (364,048) |  $ |  (3,479,047) |  $ |  (728,123) |  $ |  (8,626,326)  \nLoss per common share:  \nBasic |  $ |  (0.07) |  $ |  (0.79) |  $ |  (0.15) |  $ |  (1.98)  \nDiluted |  $ |  (0.07) |  $ |  (0.79) |  $ |  (0.15) |  $ |  (1.98)  \n  \n**NUTEX HEALTH INC.** **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** (Unaudited)  \n---  \n**Six Months Ended June 30,**  \n**2024** |  **2023**  \nCash flows from operating activities:  \nNet income (loss) |  $ |  2,467,743 |  $ |  (11,188,418)  \nAdjustments to reconcile net loss to net cash from operating activities:  \nDepreciation and amortization |  8,719,006 |  8,162,907  \nGain on warrant liability |  (5,660,843) |  –  \nImpairment of goodwill |  3,197,391 |  –  \nImpairment of assets |  3,473,635 |  –  \nDerecognition of goodwill |  453,017 |  –  \nStock-based compensation expense |  (12,074) |  2,149,645  \nDeferred tax benefit |  (2,341,262) |  (1,724,111)  \nDebt accretion expense |  579,121 |  953,236  \nLoss on lease termination |  – |  58,211  \nNon-cash lease expense (income) |  (208,423) |  61,734  \nChanges in operating assets and liabilities, net of the effects of acquisitions:  \nAccounts receivable |  (2,148,508) |  6,921,239  \nAccounts receivable – related party |  (425,121) |  (797,058)  \nInventories |  631,136 |  1,082,509  \nPrepaid expenses and other current assets |  (1,692,907) |  (3,048,993)  \nAccounts payable |  (1,617,151) |  (7,189,929)  \nAccounts payable – related party |  414,278 |  3,453  \nAccrued expenses and other current liabilities |  10,481,831 |  5,619,907  \nNet cash from operating activities |  16,310,869 |  1,064,332  \nCash flows from investing activities:  \nAcquisitions of property and equipment |  (1,291,492) |  (7,446,902)  \nCash related to sale of business |  (711,306) |  –  \nCash related to deconsolidation of Real Estate Entities |  – |  (1,039,157)  \nNet cash from investing activities |  (2,002,798) |  (8,486,059)  \nCash flows from financing activities:   \nProceeds from lines of credit |  132,167 |  1,949,919  \nProceeds from notes payable |  4,915,000 |  16,952,905  \nRepayments of lines of credit |  (594,547) |  (1,592,714)  \nRepayments of notes payable |  (6,156,543) |  (7,481,893)  \nRepayments of finance leases |  (1,440,016) |  (1,870,670)  \nProceeds from common stock issuance, net issuance costs |  9,202,500 |  –  \nMembers’ contributions |  300,850 |  649,550  \nMembers’ distributions |  (1,861,563) |  (2,686,304)  \nNet cash from financing activities |  4,497,848 |  5,920,793  \nNet change in cash and cash equivalents |  18,805,919 |  (1,500,934)  \nCash and cash equivalents – beginning of the period |  22,002,056 |  34,255,264  \nCash and cash equivalents – end of the period |  $ |  40,807,975 |  $ |  32,754,330  \n  \n**Non-GAAP Financial Measures (Unaudited)**\n\n_EBITDA and Adjusted EBITDA._ EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.\n\nWe define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.\n\nWe define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.\n\n**Three Months Ended June 30,** |  **Six Months Ended June 30,**  \n---|---  \n**2024** |  **2023** |  **2024** |  **2023**  \nReconciliation of net loss attributable to Nutex Health Inc. to Adjusted EBITDA:  \nNet loss attributable to Nutex Health Inc. |  $ |  (364,048) |  $ |  (3,479,047) |  $ |  (728,123) |  $ |  (8,626,326)  \nDepreciation and amortization |  4,532,804 |  4,169,160 |  8,719,006 |  8,162,907  \nInterest expense, net |  5,054,532 |  4,843,048 |  9,498,894 |  7,983,137  \nIncome tax expense (benefit) |  893,892 |  (815,612) |  1,283,557 |  (1,726,271)  \nAllocation to noncontrolling interests |  (1,627,829) |  (972,655) |  (3,172,002) |  (1,727,965)  \nEBITDA attributable to Nutex Health Inc. |  8,489,351 |  3,744,894 |  15,601,332 |  4,065,482  \nFacilities closing costs |  – |  – |  – |  217,266  \nGain on warrant liability |  (3,060,096) |  – |  (5,660,843) |  –  \nImpairment of assets |  3,473,635 |  3,473,635  \nImpairment of goodwill |  3,197,391 |  – |  3,197,391 |  –  \nStock-based compensation expense |  (61,241) |  249,645 |  (12,074) |  2,149,645  \nAdjusted EBITDA attributable to Nutex Health Inc. |  $ |  12,039,040 |  $ |  3,994,539 |  $ |  16,599,441 |  $ |  6,432,393  \n  \n**About Nutex Health Inc.**\n\nHeadquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.\n\nThe Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in nine states.\n\nThe Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.\n\n**Forward-Looking Statements**\n\nCertain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Report on Form 10-Q for the period ended March 31, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.\n\n![Cision](https://i0.wp.com/c212.net/c/img/favicon.png?resize=12%2C12&ssl=1) View original content:<https://www.prnewswire.com/news-releases/nutex-health-reports-second-quarter-and-six-months-ended-june-30-2024-financial-results-302218405.html>\n\nSOURCE Nutex Health, Inc.\n\n### Share this:\n\n  * [Click to share on Twitter (Opens in new window)](https://www.nutexhealth.com/nutex-health-reports-second-quarter-and-six-months-ended-june-30-2024-financial-results/?share=twitter&nb=1 \"Click to share on Twitter\")\n  * [Click to share on Facebook (Opens in new window)](https://www.nutexhealth.com/nutex-health-reports-second-quarter-and-six-months-ended-june-30-2024-financial-results/?share=facebook&nb=1 \"Click to share on Facebook\")\n\n\n\n### _Related_\n\nPosted in [news](https://www.nutexhealth.com/category/news/)\n\n![](https://pixel.wp.com/g.gif?v=ext&blog=155516726&post=3308&tz=0&srv=www.nutexhealth.com&j=1%3A14.0&host=www.nutexhealth.com&ref=&fcp=5364&rand=0.6339098393502323)\n"
        }
      ]
    },
    {
      "section_name": "Investor Deck",
      "links": [
        {
          "title": "Investor Deck",
          "url": "https://www.nutexhealth.com/wp-content/uploads/2024/08/Nutex-Health-Presentation-8-8-2024-vF.pdf",
          "content": "STRICTLY PRIVATE AND CONFIDENTIAL\nSTRICTLY PRIVATE AND CONFIDENTIAL\nDisclaimer\nGeneral\nThe information contained in this Investor Presentation (“Presentation”) has been prepared by Nutex Health Inc. (“NUTX” or the “Company”) for\ninvestors, solely for informational purposes. The Presentation has been prepared to assist prospective investors in making their own evaluation of\nthe Company and does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. The\nPresentation shall not form the basis of any contract or commitment. Information provided in this Presentation speaks only as of the date hereof\nand is subject to change. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth\nin this Presentation. This Presentation does not constitute investment, legal, tax or other advice, and does not take into consideration the\ninvestment objectives, financial situation or particular needs of any particular investor. Nothing set forth herein should be regarded or relied upon as\na representation, warranty or prediction that NUTX will achieve or is likely to achieve any particular future result. While NUTX is not aware of any\nmisstatements regarding any information in this Presentation, neither NUTX or any of its respective affiliates, officers, directors or representatives\nmakes any representation or warranty, express or implied, as to the accuracy or completeness thereof. Readers of this Presentation should consult\ntheir own counseland tax and financialadvisors as to legaland relatedmattersconcerningthe informationdescribedherein.\nThis Presentation does not purport to contain all the information or factors that may be required to make a full analysis of NUTX. Viewers of this\nPresentation should each make their own evaluation of NUTX and of the relevance and adequacy of the information and should make such other\ninvestigations as they deem necessary. This Presentation also contains estimates and other statistical data made by independent parties and by\nNUTX relating to market size and growth and other data about NUTX’s industry and peer companies. This data involves a number of assumptions\nand limitations, and you are cautioned not to give undue weight to such estimates. To the fullest extent permitted by law, in no circumstances will\nNUTX or any of its subsidiaries, affiliates, representatives, directors, officers, advisers or agents be liable for any direct, indirect or consequential\nlosses arising from the use of this Presentation, the information contained within this Presentation, or otherwise arising in connection therewith,\nincluding any investment in shares of NUTX. In addition, projections, assumptions, and estimates of NUTX’s future performance and the future\nperformanceof themarketsin which NUTX competesarenecessarily subjectto a highdegree of uncertaintyand risk.\nCONFIDENTIAL 2\nForward looking statements\nCertain statements and information included in this press release constitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Act of 1995. When used in this press release, the words or phrases “will”, \"will likely result,\" \"expected to,\" \"will\ncontinue,\" \"anticipated,\" \"estimate,\" \"projected,\" \"intend,\" “goal,” or similar expressions are intended to identify \"forward-looking statements\"\nwithin the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown,\nand uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability\nto successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No\nSurprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the\nCompany and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly\ndeveloping technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of\ntechnology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of\nfactors that can affect future results are discussed in our Annual Report on Form 10-K for the year ended December 31, 2023 under the heading\n“Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such\nfactors could materially adverselyaffect the Company's financial performance and could cause the Company's actual results for future periods to\ndiffer materially from anyopinionsor statements expressed withinthispresentation.\nCONFIDENTIAL 3\nAgenda\n1 Business Overview\n2 Appendix\nCONFIDENTIAL 4\nManagement Team With Deep Experience in Healthcare\nTThhoommaassTT.. VVoo,, MM..DD..,, MMBBAA WWaarrrreenn HHoosssseeiinniioonn,, MM..DD.. JJoonn BBaatteess,, MMBBAA,, CCPPAA JJoosshhDDeeTTiilllliioo\nCChhiieeff EExxeeccuuttiivvee OOffffiicceerr PPrreessiiddeenntt CChhiieeff FFiinnaanncciiaall OOffffiicceerr CChhiieeff OOppeerraattiinngg OOffffiicceerr\nMaster of Business Administration ER Physician CEO Co-Founder & CEO VP of Accounting CFO & CAO Master of Public Health CEO, Palm West Hospital, HCA\nMMiicchhaaeell CChhaanngg,, MM..DD.. EElliissaa LLuuqqmmaann,, JJ..DD..,, MMBBAA PPaammeellaa MMoonnttggoommeerryy,, RR..NN..,, JJ..DD..\nCChhiieeff MMeeddiiccaall OOffffiicceerr CChhiieeff LLeeggaall OOffffiicceerr ((SSEECC)) && SSeeccrreettaarryy CChhiieeff LLeeggaall OOffffiicceerr ((HHeeaalltthhccaarree))&&\nSSeeccrreettaarryy\nTeam Physician Emergency Medicine Residency CFO & General Counsel CFO & General Counsel Adjunct Professor Registered Nurse\nCONFIDENTIAL 5\nOur mission, vision, and values\nOur Mission\nTo make exceptional concierge-level health care more\naccessible to all communities, with a practice centered on\npatient experience and satisfaction\nOur Vision\nTo be leaders in individualized patient care and innovators in the\nfuture of healthcare\nOur Values\nPatient care is our number one priority – every single decision\nthat we make as a company revolves around creating the best\npossible patient care\nCONFIDENTIAL 6\nNutex at-a-glance\n Owns and operates a comprehensive and integrated care\ndelivery platform comprised of:\nCCoommppaannyy HHiigghhlliigghhttss\n Hospital Division\n– Develops and operates a network of micro-hospitals, specialty\nhospitals, and hospital outpatient departments\n– A micro-hospital is a small hospital including a full-functioning\nEmergency Room (“ER”), 4-10 inpatient suites and operated\nby Board-Certified Emergency Physicians\n– Represents ~90% of Revenue in 2023\n– 21 opened micro-hospital facilities in 2024; 4 hospitals to\nbe openedfor 2024, and 3 planned for 2025.\n Population Health Management Division\n– Risk-bearing provider networks / IPAs1\n– Cloud-based population health analytics platform\n– MSO2 that provides support services to physician groups\nincluding affiliated IPAs\n– 1 opened IPA in Los Angeles; 2 new IPAs in Houston and\nSouth Florida, with one additional expected in 20243\n Designed for Physician Leadership and Alignment 21 900+ >95% 30,000+ 3.5M 10,700+\nphysician\n Physician equity ownership in public company and real estate\nretention rate\nsince inception\n Care quality incentive payments\n Attracts and retains leading physician and team members\nNote: Company Highlights reflect values as of [Q3 2023]. 1 IPA refers to Independent Practice Associations. 2MSO refers to Management Services Organizations 3Houston and South Florida IPAs are operational, but not expected to open until 2024. CONFIDENTIAL 7\nOverview of Nutex’s hospital division\nNutex’s Innovative Micro-Hospitals Meet their served\nCommunities Demand for Higher Acuity Care Address Challenges of Traditional Care Access Points\n Network of strategically located, state-of-the-art micro-hospitals\nacross the U.S. which service ER visits at equivalent cost High volume\nWhat we  Overwhelming~140 millionvisit burden on\n Provide immediate and convenient access to both emergency emergency\ndo services and in-patient services limited ER infrastructure\nroom visits\n Offer direct admission to hospitals (if needed)\n Fulfills underserved healthcare segment of communities in need  Traditionalhospitalor ER settingscanbe\nof access to emergency and inpatient services provided by Board\nLack of unpleasant1\nWhere we Certified Physicians\nare  Target suburban, high traffic locations to facilitate ease of access convenience  Wait times tend to be very long (>100 minute\nand achieve high local visibility medianwaittime)\n “In Your Face” Go-To-Market\nNext Generation Design Serves All Stakeholders\n Patient-friendly and cost-effective setting\nOur care  Full clinical staff and open 24 hours, seven days a week\nmodel  Wait times drastically lower than traditional ER settings\n Best-in-class care delivered by friendly and attentive teams\n Reimbursed by private insurance companies as a hospital\nMicro-\nprovider\nHospital\n Collect at median in-network rates for outpatient emergency and\nRevenue\nin-patient services\nModel\n No balance billing\n1 Additional Sources: CDC, National Hospital Ambulatory Medical Care Survey: 2018 Emergency Department Summary Tables. 1Based on management estimates. CONFIDENTIAL 8\nNutex’s micro-hospitals treat over 95% of ER acuities at a fraction of the wait time\nNutex’s facilities require lower staffing and capital obligations while delivering improved quality of care, with an average patient wait time\nof 15 – 30 minutes\nU.S. National Average ER Acuity Levels\n90% of ER acuities are levels 2 –4 and are covered at Nutex’smicro-hospitals\n1 2 3 4 5\nNon-urgent Semi Urgent Urgent Emergent Immediate\n(Rash) (Simple laceration) (Abdominal pain) (Asthma attack) (Cardiac arrest)\nComparing the percentage of patients We treat a wide range of patient\ntreated at NUTX to U.S. ER Averages demographics… … Experiencing a variety of ailments\nNUTX\nAcuity National\nAverage ∆ PPeeddiiaattrriiccss ((<<1188)) Abdominal Pain\nLevel Average\n(2023) RReepprreesseennttss 1188%% ooff ppaattiieennttss Chest Pain\n1 1% 3% (0%) Broken Bones\nYYoouunngg aadduullttss ((1188~~3355)) Injuries and Wounds\n2 6% 18% (13%)\nRReepprreesseennttss ~~3311%% ooff ppaattiieennttss Flue-like Symptoms\n3 35% 35% 0% Vomiting / Diarrhea\nAAdduullttss ((3355++)) Cough\n4 39% 10% 29%\nRReepprreesseennttss ~~5511%% ooff ppaattiieennttss Headaches\n5 13% 3% 10%\nCONFIDENTIAL 9\n1 Source: CDC, National Hospital Ambulatory Survey: 2021 ED Summary Tables 2 The remaining 8% for the U.S. ER average is attributed to no triage 3 BCBS is comprised of 8 different independent State Payors Plus BCBS Federal\nTurn-key de novo strategy delivering compelling and scalable facility economics\nDe Novo Facility Profile De Novo Rollout Timeline\n Provide emergency, inpatient care, outpatient imaging, outpatient Task Timing\nlabs, minor procedures, etc.\nServices / Staffing\n ER Physician, RNs, Radiology Technologists, EMT with on-call\nHospitalist on staff at all times\nIdentify Optimal Markets > 18 months before entry\n ~18,000 sq ft\nSize & Beds\n 4-10 in-patient beds; 6-10 emergency rooms\n Target densely populated suburban and underserved markets\n(with a focus on populations covered by commercial payers) Evaluate Site Feasibility 12 -18 months before entry\nSite Selection and\n Evaluate demographics, real estate costs, coverage and\nEvaluation\ncompetitive landscape\n Conduct regulatory and state / municipality research\n Capex –around $3.5-4mm per facility to open Build Sites 0 -12 months leading to entry\nCost\n Cost of real estate –roughly $15-20mm per facility\n Typical facility is cash flow positive within ~12-13 months\nProfitability\n Achieve breakeven at ~15-20 patients per day\nAccelerated Market\n Pipeline of in-development and early planning facilities; expect to Ongoing (once site is open)\nbuild +5 facilities per year1 Growth and Expansion\n Embedded growth of newly opened facilities to maturity\nGrowth\nsupported by marketing and other business development\n Expand service line offerings Total time frame for opening a typical new facility is ~18 months\n Hub and spoke model including new types such as Urgent Care\n1Management guidance per FY 2022 10K filing. Nutexplans to nearly double its facility footprint by mid-2025 with 4 facilities opened in 2023, 5 new facilities in 2024, 5 in 2025. CONFIDENTIAL 10\nOverview of Nutex’s population health management division\n Nutex operates 3 IPAs:\nCCoommppaannyy HHiigghhlliigghhttss\n Clinical quality reporting (STAR, HEDIS, MIPS, ACO reports)\n Nutex IPAs (Independent Practice Associations)\n AHP IPA (Los Angeles): 25,000 patients, 140+ primary care\nphysicians, 400+ specialists\n An IPA is a network physicians that contracts with payors\nand manages the total care of patients\n Houston Physicians IPA: 1200+ patients, 70+ primary care\nphysicians\n Our IPAs are risk-bearing organizations: they assume\neither partial or full risk\n South Florida: 4200+ patients, 120+ primary care physicians\n Partial risk: IPAis responsible for paying physicians only\n Phoenix Physicians IPA: is expected tobe operational in\n2024.\n Full risk: IPA is responsible for paying physicians and\nhospitals as well as other providers\n Our IPAs pay physicians either via fee-for-service or\ncapitation\nDefinitions: ACO: Accountable Care Organization; CQM: Clinical Quality Measure; EHR: Electronic Health Record; HCC: HierarchicalCondition Categories; HMO: Health Maintenance Organization; IPA: Independent Practitioner Association; CONFIDENTIAL 11\nMSO: Management Services Organization; RAF: Risk Adjustment Factor; SaaS: Software-as-a-Service ; Houston and South Florida IPAs are operational, but not expected to open until 2024\nOur vision is to create a coordinated, integrated, risk-bearing care delivery model\n Pioneering platform which\ncombines a national network of\npatient-centric micro-hospitals\nwith wraparound technology-\nenabled primary care\nNetwork of micro- Risk-bearing\nhospitals provider capabilities\nnetworks\n Proven track record in\nproviding high-quality, more\ncost-efficient care relative to\ntraditional hospital care setting\n Supported by proprietary,\nRobust back- Data\ncloud-based technology\noffice teams analysis\nsystem that analyzes and\naggregates data across its\nPatient-centric healthcare Technology enabled value- entire healthcare delivery\nplatform\nprovider based network\n Robust care coordination\nBilling & MSO capabilities with active patient\ncollections services management to improve\noutcomes for all partiesand\ndrive greater payor adoption\nToday Future State  Uniquephysician-led structure\nMicro-hospitals Value-based care\nand ownership model drives\nsuperior patient experience and\nquality outcomes\nFirst-of-its-kind integrated healthcare delivery model\nCONFIDENTIAL 12\nNutex Health Differentiators\nNutex Health has two divisions: The Micro-Hospital Division and the Population Health Division\n Micro-Hospital  Population Health Management:\n Clean, new facilities with private rooms  Expertise in providing high quality, cost-efficient care\n Reduced Emergency Department wait-times: average 15-  Expertise in managing complex, chronically ill patients\n30 minutes versus hours\n Leverage integrated platform to actively manage patients\n 24/7/365 accessibility\nand enhance care coordination. Micro-hospital\nemergency departments can be used as high-risk clinics\n Increased patient convenience and patient satisfaction\nand post-discharge clinics\n Higher reimbursement rates than an urgent care center or\n Built on the emerging trend of value-based care\ndoctor’s office\n Data analytics: past, present and predictive\n Less costly to build than a larger hospital\n Ability to take financial risk profitably\n Quicker way to expand geographic footprint\n Engaged ED physicians with less physician burnout\nThe combination of the two divisions is expected to increase volumes to the micro-hospitals while reducing medical expenses on the IPA side, resulting in decreased medical loss ratios (MLRs).\nCONFIDENTIAL 13\nOur focus areas represent a massive market opportunity\nPopulation Health Management Division\nI) Clinigence – cloud-based SaaS and data analytics enable providers to optimize clinical\nPopulation Health outcomes and financial performance\nII) Procare – an MSO that provides healthcare administration and management services\nValue-Based Care\nIII) AHP – Southern California risk-bearing IPA; 900+ Physicians with 30K+ lives\nTotal Emergency Department Market\nTotal\n All payors\nAddressable\n All levels of acuity\nMarket  Open 24/7, 365\n ER services, advanced imaging, scheduled procedures, testing and lab services to\n~$280 billion\nadult and pediatric patients\nTargeted Emergency Department Market\nTargeted\n ER services, inpatient, outpatient imaging, outpatient labs, minor procedures, etc.\nAddressable\n Suburban and underserved markets\nMarket  Commercial pay Emergency Department (“ED”) visits\n Mid-acuity (emergent to semi-urgent) cases\n~$110 billion\nSource: U.S. Department of Commerce, U.S. Department of Health and Human Services Centers for Disease Control and Prevention,National Hospital Ambulatory Medical Care Survey: 2018 Emergency Department Summary Tables CONFIDENTIAL 14\nNote: 2022 Segal Health Plan Cost Trend Survey Report indicates the average cost of an ER visit to be as high as ~$1,900\nSelected External Growth Opportunities\nCore NutexOpportunities Emerging Nutexand Micro-Hospital Opportunities\nIPA Development Joint Ventures\n Acquire or start IPAs  Develop and operate facilities on behalf of health\n Increase capitation and full-risk contracting systems\nFacility Development Digital Health\n Acquire and transition facilities into micro-hospitals  Telehealth support\n Hospital outpatient licensing  Radiology AI\n Improve MLR on risk-bearing contracting\nStrategic Geographies Partnerships\n Enter new markets  Employer direct health\n Add density in served markets  Support additional models to augment patient\n Certificate of Need states volume\nService Line Expansion Emerging Care Models\n Brick and mortar support needs across psych,  Continuous care model support\ntelemedicine and others  Chronic disease management network\n After-hours urgent care\n Support IPA care delivery\nCONFIDENTIAL 15\nFinancial Overview\nHHiissttoorriiccaall FFiinnaanncciiaallss --AAnnnnuuaall CCoommmmeennttaarryy\n Total revenue of $247.6 million as compared to total\nrevenue of $219.3 million for the year ended\nDecember31,2022.\n($ in millions)  Net loss attributable to Nutex Health Inc. of $45.8\nmillion (including a non-cash asset impairment charge\nof $29.1 million and a $1.1 million goodwill\nimpairment charge for hospital closures) as compared\nto net loss attributable to Nutex Health Inc. of $424.8\nmillion (including a non-cash goodwill impairment\nchargeof$398.1million)fortheyearendedDecember\n31,2022.\n Adjusted EBITDA of $10.8 million as compared to\nAdjusted EBITDAof $12.6 million for the year ended\nDecember31,2022.\n Netcashfromoperatingactivitiesof$1.3million.\n As of December 31, 2023, the Company had total\nassets of $398.2 million, including cash and cash\nequivalentsof$22.0million.\n Continued focus on increased cash flow through\nreduction in operating expenses and portfolio\noptimization\n CONTINUED FOCUS ON INCREASED\nNote: FY2019 consolidated EBITDA is not available per publics filings. 2021 results benefitted from higher patient volumes due to COVID-19 related cases. Adjusted EBITDA is a non-GAAP finaCnciaAl mSeaHsure. FForL adOditioWnal infoTrmHatioRn oOn noUn-GGAAHP finanRciaEl DCUONCFTIDIOENNTIAILN16\nmeasures and a reconciliation to the most comparable GAAP measures, see \"Non-GAAP Financial Measures\" in our Quarterly Report onForm 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 9, 2023.\nOPERATING EXPENSES AND PORTFOLIO\nFinancial Overview\nHHiissttoorriiccaall FFiinnaanncciiaallss -- QQuuaarrtteerrllyy CCoommmmeennttaarryy\nFinancial Highlights for the Three Months Ended June 30, 2024:\n Total revenue of $76.1 million as compared to total revenue of\n$58.9 million for the three months ended June 30, 2023, an\nincrease of 29%. Of this revenue growth, mature hospitals,\nwhich are hospitals opened prior to December 31, 2021,\nincreased by 13.2% in 2024 compared to the same period in\n2023.\n Net loss attributable to Nutex Health Inc. of $0.4 million as\ncompared to net loss attributable to Nutex Health Inc. of\n$3.5 million for the three months ended June 30, 2023. This\nincludes non-cash impairment of assets of $3.5 million, non-cash\nimpairment of goodwill of $3.2 million and $3.1 million non-\ncash gain on warrant liability.\n EBITDA, attributable to Nutex Health Inc. of $8.5 million as\ncompared to EBITDA, attributable to Nutex Health Inc. of $3.7\nmillion for the three months ended June 30, 2023.\n Adjusted EBITDA, attributable to Nutex Health Inc. of $12.0\nmillion as compared to Adjusted EBITDA, attributable to Nutex\nHealth Inc. of $4.0 million for the three months ended\n($ in millions) June 30, 2023, an increase of 200%.\n Total visits from the Hospital Division were 41,208 for the\nsecond quarter 2024 as compared to 32,183 for the second\nquarter 2023, an increase of 9,025 or 28.0%. Of this visit growth,\nmature hospitals increased by 10.3% in 2024 compared to the\nsame period in 2023.\nNote: FY2019 consolidated EBITDA is not available per publics filings. 2021 results benefitted from higher patient volumes due to COVID-19 related cases. Adjusted EBITDA is a non-GAAP financial measure. For additional information on non-GAAP financial CONFIDENTIAL 17\nmeasures and a reconciliation to the most comparable GAAP measures, see \"Non-GAAP Financial Measures\" in our Quarterly Report onForm 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 9, 2023.\nBoard of Directors With Deep Experience in Healthcare\nThomas T. Vo, M.D., MBA\nChief Executive Officer\nScott J. Saunders Kelvin Spears, M.D.\nDirector Director\no Mr. Saunders is head of health care advisory services and has been Managing o Dr. Spears is Board Certified in Emergency Medicine and has over 32 years of\nWarren Hosseinion, M.D. Director of Farlie Turner Gilbert & Co., LLC, a boutique middle market emergency medicine experience.\ninvestment bank, since 2006. Since 1992, he has served as a financial and o Dr. Spears also serves as the EMS Medical Director for Alexandria Fire\nPresident and Director strategic advisor to middle market companies across a variety of industries, Department, Pineville Fire Department, CotileFire Department, Central Louisiana\nincluding companies primarily in the healthcare industry. Bureau EMS, Kisatchie Forest/US Forest Service and Rapides Parish School.\no Mr. Saunders received his B.A. degree from Wesleyan University and his MPPM\ndegree from the Yale University School of Management.\nCheryl Grenas, R.N., MSN Mike Reed Mitchell Creem\nDirector Director Director\no Ms. Grenascurrently serves as the Chief Nursing Officer at Behavioral Hospital of o Mr. Reed was President and CEO of Team Health Hospital Medicine, a o Mr. Creem has spent over 30 years as a \"C-level\" executive of\nBellaire and was a consultant to start-up and existing freestanding emergency division of TeamHealth, a publicly-traded company that was acquired various healthcare organizations.\ndepartments in the Houston Metropolitan area. by Blackstone in 2017. o Mr. Creem has served as President of The Bridgewater Healthcare\no Ms. Grenasserved in the US Navy for 20 years, achieved the rank of Lieutenant o He served as the Chief Operating Officer of Pinnacle Health System, a Group and the CEO and CAO of Verity Health System, a six-hospital\nCommander, and is a veteran of two deployments in support of Operation Iraqi\nhealth care solutions company providing outpatient, inpatient, claims, system in California.\nFreedom (2005) and Operation Enduring Freedom (2011).\nbilling, and medical management. o He served as the CFO and Board Member of Apollo Medical\nHoldings, Inc. (NASDAQ: AMEH)\nCONFIDENTIAL 18\nInvestment Highlights\nWell-positioned for major trends in a large and attractive market (high-quality, medium-acuity patient-\n1\ncentric hospital with inpatient care and value-based outpatient care)\nDeep value proposition to the healthcare ecosystem from our comprehensive portfolio of coordinated\n2 assets, and the synergistic relationship between our population health division and hospital division,\ndelivering high-quality, cost-effective care and high levels of patient satisfaction.\n3 Long-term alignment with local Patients, Physicians, and Payors. A win/win/win for all 3 stakeholders:\nMultiple levers for long-term growth with 22 opened micro-hospital facilities in 2024; 4 hospitals slated\n4\nfor 2024, and 5 slated for 2025.\nNew Risk Bearing Network to complement hospital locations in Houston and South Florida. This is in\n5\naddition to the existing network in Los Angeles.\nCost of Real Estate is financed by third party private investors and does not affect Nutex Health cash\n6\nflow.\n7 Ground level investment opportunity for third party capital and physicians alike.\nStrong management team and Board of Directors with unparalleled expertise in the industry and proven\n8\nability to execute\nCONFIDENTIAL 19"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://www.nutexhealth.com/sec-filings/",
          "content": "[Skip to content](#fl-main-content)\n\n[![Nutex Health](https://www.nutexhealth.com/wp-content/uploads/2020/10/nutex-health-logo-color-blue-lined-circle-2.png)](https://www.nutexhealth.com/)\n\n☏ 713-660-0557 ✉ info@nutexhealth.com\n\n[Facebook](https://www.facebook.com/nutexhealth/)[Twitter](https://twitter.com/nutexhealth)[Linkedin](https://www.linkedin.com/company/nutex-health-inc)\n\n[![Nutex Health](https://www.nutexhealth.com/wp-content/uploads/2020/10/nutex-health-logo-color-blue-lined-circle-2.png)](https://www.nutexhealth.com/)\n\n#  SEC Filings\n\n## Latest Filings\n\n##  SEC Filings\n\n[ Annual Reports ](https://www.nutexhealth.com/annual-reports/)\n\n[ Quartely Reports ]()\n\n[ Section 16 Filings ](https://www.nutexhealth.com/section-16-filings/)\n\n![](https://pixel.wp.com/g.gif?v=ext&blog=155516726&post=2072&tz=0&srv=www.nutexhealth.com&j=1%3A14.0&host=www.nutexhealth.com&ref=&fcp=5968&rand=0.7543988917137636)\n"
        }
      ]
    }
  ]
}